The trailing P/E of 122.92 reflects heavily depressed GAAP net income driven by amortization and impairment charges, so it carries limited analytical weight on its own. The forward P/E of 20.85 and forward EV/EBITDA of 14.83 imply the market expects earnings to normalize, which investors should test against gross-to-net pressure and the Humira erosion trajectory. Relative to peers, these forward multiples sit within the range of JNJ and AMGN, which may indicate the market treats the immunology pipeline as partially de-risked.

The gap between operating and net margin is wide, and across the ten-quarter history it swings sharply, with net margin falling to 0.1% in 2025Q3 while operating margin was 12.1%. This pattern suggests GAAP earnings are a weak proxy for earning power, and investors should monitor whether operating margin can hold near 30% or more once IRA price negotiations take effect. Compared with JNJ at 28.5% and MRK at 28.1% net margin, AbbVie's underlying profitability appears competitive but its reported figures are noisier.

The swing in interest coverage between quarters reflects the volatility of operating income more than structural deleveraging, as debt-to-EBITDA remains elevated at 12.48x in the latest quarter. Debt-to-equity is no longer meaningful given negative book equity, so coverage and debt-to-EBITDA are more informative. Peers such as BMY at a 2.55 debt-to-equity and AMGN at 6.31 indicate AbbVie's leverage is high but not an outlier, and refinancing risk warrants further investigation given total debt of roughly $80.9B.

A sub-1.0 current ratio is common among large pharmaceutical companies with high deferred revenue and short-term debt, but its persistence across ten quarters warrants monitoring. The quick ratio of 0.75 in 2026Q3 indicates inventory is not the primary driver, so the gap likely reflects current debt maturities and accrued obligations. Under severe stress, the company would depend on continued operating cash flow and capital market access rather than liquid asset reserves.